Kornimate/medical-research-clean huggingface dataset:
mobile phone intervention to reduce youth suicide in rural communities

Conditions: Help-Seeking Behavior; Emotions; Trusted Adults; Suicide; Positive Affect

Summary: the goal of this research project is to conduct a pilot rct of text4strength, an interactive automated text messaging extension of sources of strength (sos), a universal school-based suicide prevention program that prepares diverse 'key opinion leaders' to conduct public health messaging and activities with peers to increase school-wide positive coping norms, communication with trusted adults, and seeking help for suicidal peers (wyman et al., 2010). the investigators previously developed and field tested text4strength messages (rsrb#00047481 and 53924 closed) to demonstrate feasibility, safety, student engagement, and student-perceived relevance for a universal texting extension. the investigators will now conduct a pilot randomized controlled trial in one large school in western new york that has implemented sources of strength for the past two years. the school will continue with sources of strength in the 2016-17 school, and add this school-wide texting component as part of this research study. consistent with leon's guidelines on pilot studies, the primary focus will be to identify areas of promise, success in reaching proximate targets, and the need for additional modifications (leon, davis, \& kraemer, 2011). findings from this study will inform further refinement of the text messaging program and provide preliminary data for a larger efficacy trial.


Eligibility criteria:
inclusion criteria: * 9th-12th grade students in study school * must have own cell phone exclusion criteria: * no cell phone * not sufficiently english-speaking to complete surveys
compare different response evaluations to neoadjuvant chemotherapy for gastric cancer

Conditions: Gastric Cancer

Summary: rationale: neoadjuvant chemotherapy has been proved effective for locally advanced gastric cancer, yet the best pattern of response evaluation remain unknown. purpose: compare different pattern of response evaluation for gastric cancer.

objectives: i. find the best pattern for response evaluation for gastric cancer. ii. assess the factor associated with this pattern. outline: neoadjuvant chemotherapy. projected accrual: up to 150 patients will be accrued over approximately 2 years.

Eligibility criteria:
inclusion criteria: * sign written informed consent form * age ≥ 18 years * pathologically confirmed gastric or gej adenocarcinoma * disease at clinical stage of locally advanced gastric cancer by ct/eus(ct2+nanym0) * no prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy * adequate organ function as defined below: hematologic anc ≥ 1.5\*109/l hemoglobin ≥ 9 g/dl platelets ≥ 100\*109/l hepatic albumin ≥ 30g/l serum bilirubin ≤ 1.5×uln ast and alt ≤ 2.5×uln alp ≤ 2.5×uln tbil ≤ 1.5×uln renal serum creatinine \< 1.5 uln * kps ≥ 70 * adequate lung and heart function * negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women * sexually active males or females willing to practice contraception during the study until 30 days after end of study. exclusion criteria: * refuse to provide blood/tissue sample； * with distant metastasis diagnosed by ct/eus； * sexually active males or females refuse to practice contraception during the study until 30 days after end of study. * history of organ transplantation（including autologous bone marrow transplantation and peripheral stem cell transplantation）； * prior long term steroid therapy (excluding short term steroid treatment which is completed prior to \> 2 weeks of study enrollment)； * patients with central nervous system(cns) disorder or peripheral nervous system disorder or psychiatric disease； * concurrent severe infection； * concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety (including current active hepatic, biliary, renal, respiratory disease, uncontrolled diabetes hypertension et al)； * history of other malignancy. however, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible； * known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency； * person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons.

Keywords: gastric cancer neoadjuvant chemotherapy response evaluation
melatonin for cerebral palsy children's sleep and health

Conditions: Cerebral Palsy; Melatonin; Growth; Children, Only

Summary: the present study was prospective uncontrolled, single-armed and un-blinded study. held in the pediatric neurology clinic, children's hospital l, faculty of medicine, ain shams university from june 2016 to june 2018 of 24 months timeframe. all cerebral palsy (cp) patients following up in pediatric neurology clinic aged between 2 and 12 years. melatonin given for 3 months. anthropmetric measures, gastroeintestinal symptoms, children's sleep habits questionnaire (cshq) arabic version, polysomnography, chalfont epilepsy severity score, and eeg were done at enrollment and after the 3-months.

a prospective, cohort study conducted in pediatric neurology clinic, children's hospital, faculty of medicine, ain shams university. forty children with scp with sleep and seizure problems, aged 2-12 years were enrolled. the children received crushed melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months. children's sleep habits questionnaire (cshq) arabic version, polysomnography, chalfont epilepsy severity score, and eeg were done at enrollment and after the 3-months. the ethical approval number is (fmasu md 202/2016).

Eligibility criteria:
inclusion criteria: * all cerebral palsy children with sleep problem and seizure disorder, * aged 2 - 12 years exclusion criteria: * any auditory and peripheral visual impairments

Keywords: children's sleep habits questionnaire (cshq) arabic version anthropometry gerd constipation polysomnography
the prevalence of neurocognitive disorder in a primary care-based hiv cohort compared to a hiv-negative control cohort -

Conditions: HIV-1-Associated Cognitive Motor Complex

Summary: to determine the prevalence of hiv associated neurological disorder (hand) in a population of hiv positive patients within a primary care setting compared with the hiv negative population. the investigators aim is to assess the use of optimal screening methods to assess hand. for this the investigators will be comparing the performance of a group of persons who are hiv positive and a group of persons who are hiv negative to test their memory and concentration abilities over-time.


Eligibility criteria:
hiv positive inclusion criteria: * documented hiv infection * able to participate in study procedures hiv positive exclusion criteria: * inability to comprehend or read english (as established by the english proficiency questionnaire) * drug or alcohol intoxicated (as determined by the investigator) * lack of information in medical records to determine the hand predictive algorithm (current cd4 count, past cns hiv-related disease, and duration of hiv therapy) * life expectancy \<6 months * inability to attend the clinic for required study follow up visits hiv-negative inclusion criteria: * negative hiv-1 test within 12 months of study entry hiv-negative exclusion criteria: * life time traumatic brain injury leading to loss of consciousness of at least 30 minutes. * inability to comprehend or read english (as established by the english proficiency questionnaire). * inability to attend the clinic for required study follow up visits. * history of chronic neurological illness. * unstable psychiatric conditions such as bipolar disorder or depression. * individuals with psychiatric disorder on the psychotic axis. * active or past (within the last 6 months) severe alcohol or substance abuse sufficient, in the investigator's judgement, to prevent completion of tests or inability to attend for the planned required study follow up visits.

Keywords: hiv neurocognitive disorder primary care hiv negative hand cns
all-extremity exercise during breast cancer chemotherapy

Conditions: Breast Cancer

Summary: currently, there are 3.5 million breast cancer survivors in the united states and this number is expected to increase dramatically. the proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. findings may have implications for cardiovascular disease prevention in this population.


Eligibility criteria:
inclusion criteria: * active diagnosis of primary invasive non-metastatic breast cancer, stages i-iii * female * 18 to 85 years of age * scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane) * absence of contraindications to exercise * study clinician approval * able to give consent * informed consent obtained from the subject and documentation of subject agreement to comply with study-related process exclusion criteria: * do not meet inclusion criteria * receiving targeted therapies (cdk4/6 or parp inhibitors) * receiving radiation therapy concurrent with chemotherapy * lymphedema stage ≥ 2 prior to study enrollment * any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
patient satisfaction in cutaneous surgery

Conditions: Skin Cancer

Summary: the primary objective of this study is to measure the overall level of satisfaction in patients after cutaneous surgery in 4 different categories, including the surgeon, facility, procedure and recovery and outcome.

secondary objectives are to identify factors associated with patient satisfaction level and determine the correlation between patient satisfaction and surgeon clinical perception.

Eligibility criteria:
inclusion criteria: * 18-80 years old * is in a self-reported stable health condition * english speaking * is willing and has the ability to understand the study, provide informed consent and communicate with the investigator * recommended to have and scheduled for cutaneous surgery * agrees to follow-up at scheduled times exclusion criteria: * unable to speak or read english * did not complete an 8th grade education * a history of mental illness * any other disability or condition that would prevent completion of questionnaire
novel biophotonics methodology for colon cancer screening

Conditions: Colon Cancer

Summary: this is a proposal to establish a bioengineering research partnership (brp). the major objective of the brp is to refine and provide comprehensive, definitive multi-center validation of these novel methodologies for colorectal cancer (crc) screening, thus providing a quantum leap in population screening.

background and significance highlights the impracticality to provide total colonic evaluation for the entire population. risk-stratification via exploitation of the "field effect" is an attractive approach. however, all existing methodologies (e.g fobt, fecal dna, flexible sigmoidoscopy) are clearly suboptimal underscoring the need for novel tools for identifying the field effect. 1) we have developed elf/lebs for depth-selective (from \~30 to hundreds of microns) spectroscopic assessment of living tissue. 2) we tested these novel techniques in two animal models of crc (the aom-treated rat and min-mouse) and in human subjects (n=190). we demonstrated that elf/lebs has the potential to detect precancerous changes in the colon at a time point that precedes the formation of adenomas and other histological/molecular markers of crc. 3) we demonstrated that rectal elf/lebs can detect field effect alterations in histologically normal rectal tissue changes due to the presence of adenomas anywhere in the colon. in our pilot studies, the diagnostic accuracy of rectal elf/lebs far exceeded any other currently known markers of crc. therefore, assaying elf/lebs in the rectum has the potential to provide accurate risk-stratification for colon carcinogenesis without the need for bowel preparation and colonoscopy. 4) we have developed prototypes of elf and lebs fiber-optics probes for in vivo use.

Eligibility criteria:
inclusion criteria: * subject is 18 years old or older and is having a colonoscopy procedure. exclusion criteria: * concurrent usage of anticoagulation or blood thinner medication within the last 7 days that would preclude hx of inflammatory bowel disease/colitis/chemotherapy.

Keywords: novel biophotonic methodology for colon cancer screening.
clinical and radiographic evaluation of indirect pulp capping using platelet rich fibrin versus mineral trioxide aggregate in deep carious molars: a randomized controlled trial

Conditions: Dental Caries; Pulp Caping; Indirect Pulp Treatment; Indirect Pulp Cap; Indirect Pulp Capping; Indirect Pulp Therapy; Deep Carious Lesion; Deep Carious Lesions; Molar Caries; Carious Molars

Summary: the aim of this study is the clinical and radiographic evaluation of (platelet-rich fibrin (prf) versus mineral trioxide aggregate (mta) in indirect pulp capping when used with deep carious molars over 1 year follow up.

-picots : p: asymptomatic deep carious molars. i: indirect pulp capping using prf. c: indirect pulp capping using mta. o: outcome name measuring device measuring unit primary outcome: clinical findings : pulp sensibility using cold test (sharma a et al., 2020). secondary outcome: radiographic findings :dentin bridge measurement in mm using digital radiographic ruler digital periapical using paralleling technique (sharma a et al., 2020). t: t0: baseline t1: 3 months t2: 6 months t3: 12 months s: randomized clinical trial. - research question: will prf provide comparable clinical and radiographic outcomes to mta in indirect pulp capping when used in deep carious molars?

Eligibility criteria:
inclusion criteria: * o patients with asymptomatic deep carious molars. * patients with clinically and radiographically confirmed deep carious lesions that do not exhibit spontaneous pain. * permanent molars only. * teeth with intact or minimally restored occlusal surfaces (i.e., no extensive restorations or fractures). * no history of previous endodontic treatment or direct pulp capping on the study tooth. * no signs of periapical pathology based on radiographic evaluation. * patients willing to participate and follow up for 12 months. * patients who agree to return for scheduled follow-ups at 3, 6, and 12 months. exclusion criteria: * o patients with systemic conditions affecting bone or tissue healing (e.g., uncontrolled diabetes, osteoporosis, immunosuppressed conditions). * pregnant or lactating women (if applicable to your study). * teeth with pulp exposure or necrotic pulp. * presence of symptomatic irreversible pulpitis (e.g., spontaneous pain, lingering pain). * periapical pathology or internal/external resorption detected radiographically. * severely broken down or non-restorable teeth. * calcified root canals or excessive sclerosis that could affect pulp testing reliability. * any pre-existing root canal treatment on the selected tooth. * patients who have undergone recent fluoride treatment, pulpotomy, or other pulp therapies in the past 6 months. * patients using medications affecting bone and tissue regeneration (e.g., bisphosphonates, corticosteroids). * patients unwilling or unable to commit to the 12-month follow-up schedule. * patients with poor oral hygiene or high caries risk that could compromise treatment outcomes.

Keywords: molar caries mta prf indirect pulp capping deep carious lesion carious molars platelet rich fibrin
evaluation of the antalgic effect of puressentiel joints and muscles - gel on joint pain of the knee

Conditions: Pain; Joint Pain

Summary: this clinical trial aims to evaluate the antalgic effect of puressentiel joints and muscles - gel with 14 essential oils for 12 weeks on knee joint pain in 45 patients suffering from chronic pain related to arthritis of the knee. the evaluation of the puressentiel antalgic effect joints and muscles - gel with 14 essential oils will be done by an algo-functional score of womac based on items of pain, joint stiffness and locomotor function (main criterion), a visual analog scale eva (graduated from 1 to 10) of the pain by self-assessment of the patient during the consultation and the number of daily analgesics and anti-inflammatory drugs (secondary criteria).

this clinical trial aims to evaluate the antalgic effect of puressentiel joints and muscles - gel with 14 essential oils for 12 weeks on knee joint pain in 45 patients suffering from chronic pain related to arthritis of the knee. the patients included in the study will be consultants from the department of physical medicine, rehabilitation and sports trauma at foch hospital in suresnes and will have to present chronic pain related to arthritis of the knee either with or without antalgic and anti-inflammatory treatment. the evaluation of the puressentiel antalgic effect joints and muscles - gel with 14 essential oils will be evaluated by an algo-functional score of womac based on items of pain, joint stiffness and locomotor function (main criterion), a visual analog scale eva (graduated from 1 to 10) of the pain by self-assessment of the patient during each visit and the number of daily antalgic and anti-inflammatory drugs (secondary criteria).

Eligibility criteria:
inclusion criteria: * subject smust be able to understand the terms of the written informed consent and must agree to date and sign it before any study procedure is carried out, * patient having signed the informed consent * aged 45 to 90 * with chronic osteoarthritis of the knee * patient with or without analgesic and anti-inflammatory treatment exclusion criteria: * patient at the stage of surgical osteoarthritis (grade 4 plus limitation of amplitude) * patient with a limited walking perimeter (\<100m) for any reason whatsoever * patient allergic to one of the components of the study product * patient not benefiting from social security * patient cannot be followed for the duration of the study * participation in another clinical trial within 30 days before v0 * subjects who cannot understand or perform study procedures. * pregnant or breastfeeding women * people with a history of convulsive or epileptic disorders * people allergic to salicylates.

Keywords: pain arthritis knee
long-term safety and tolerability of bhv-7000

Conditions: Focal Epilepsy

Summary: a study to determine if bhv- 7000 is safe and tolerable in adults with refractory focal onset epilepsy


Eligibility criteria:
key inclusion criteria: * subjects who completed the double-blind phase (dbp) of prior parent study, bhv7000-302 or bhv7000-303. * (focbp) females of child bearing potential must have a negative urine pregnancy test at the baseline/day 0 visit key exclusion criteria: * any condition, such as an ongoing ae with/without sequelae, or is poorly tolerating ip in the double-blind phase of the parent study, that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the investigator. * any medical condition, based on the judgement of the investigator, that would confound the ability to adequately assess safety and efficacy outcome measures

Keywords: focal epilepsy epilepsy seizure refractory epilepsy partial epilepsy
mcce in assessing efficacy of gastro-oesophageal varices

Conditions: Gastroesophageal Varices

Summary: this study proposed for the first time the use of mce to evaluate the efficacy of the treatment of gastroesophageal varices, and compared the examination results with the gold standard to explore whether mce could replace the electronic gastroscopy as the preferred non-invasive evaluation method for the treatment of gastroesophageal varices.

gastro-esophageal varices is one of the complications of portal hypertension in cirrhosis. for patients with moderate to severe varicose veins, international guidelines recommend active treatment, including endoscopic therapy such as endoscopic band ligation (ebl) and interventional radiotherapy such as balloon-occluded retrograde transvenous obliteration (b-rto)electronic gastroscopy is the gold standard for the diagnosis of varicose veins at higher blood risk (varicose veins requiring retreatment). however, it is relatively invasive and uncomfortable in the examination process, so that patients with gain-and-compensation cirrhosis are often unwilling to accept it, which is not conducive to the standardized follow-up after the treatment of gastro-esophageal varices.magnetically controlled capsule endoscopy (mce) is a non-invasive detection method independently developed in china that covers the whole digestive tract (except colon) mucosa. patients only need to swallow a capsule endoscope to make repeated observation for many times, and the examination process is painless. it is an ideal method for diagnosing varicose veins with high blood risk (varicose veins that need treatment). therefore, this study proposed for the first time the use of mce to evaluate the efficacy of the treatment of gastroesophageal varices, and compared the examination results with the gold standard to explore whether mce could replace the electronic gastroscopy as the preferred non-invasive evaluation method for the treatment of gastroesophageal varices.

Eligibility criteria:
inclusion criteria: * 18-75 years old * confirmed cirrhosis by clinical or pathological biopsy * previous endoscopic treatment of esophageal and gastric varices, including but not limited to sclerotherapy, injection of tissue adhesives, skin entrapment, etc * electronic gastroscopy is to be performed * voluntary informed consent exclusion criteria: absolute contraindications: * patients without surgical conditions or refusing any abdominal surgery (once the capsule is stranded, it cannot be removed by surgery) * there is a pacemaker in the body, except that the pacemaker is a new mri compatible product * electronic devices such as cochlear implants, magnetic metal drug infusion pumps, nerve stimulators and magnetic metal foreign bodies are implanted in the body; * .women during pregnancy relative contraindication: * gastrointestinal obstruction, stenosis, and fistula are known or suspected * dysphagia